Vir Biotechnology - VIR Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $33.57
  • Forecasted Upside: 218.21%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$10.55
▼ -0.1 (-0.94%)

This chart shows the closing price for VIR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vir Biotechnology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VIR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VIR

Analyst Price Target is $33.57
▲ +218.21% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Vir Biotechnology in the last 3 months. The average price target is $33.57, with a high forecast of $110.00 and a low forecast of $12.00. The average price target represents a 218.21% upside from the last price of $10.55.

This chart shows the closing price for VIR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 investment analysts is to moderate buy stock in Vir Biotechnology. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/2/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/2/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/31/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$110.00Low
5/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$110.00Low
5/3/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$15.00Low
5/3/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$10.00 ➝ $12.00Low
3/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$110.00N/A
2/23/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$9.00 ➝ $10.00Low
2/14/2024HC WainwrightBoost TargetBuy ➝ Buy$85.00 ➝ $110.00Low
1/29/2024JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$23.00 ➝ $9.00Low
1/23/2024HC WainwrightLower TargetBuy ➝ Buy$95.00 ➝ $85.00Low
11/3/2023Needham & Company LLCLower TargetBuy ➝ Buy$22.00 ➝ $15.00N/A
9/8/2023Bank of AmericaDowngradeBuy ➝ Neutral$23.00 ➝ $14.00Low
8/7/2023HC WainwrightLower TargetBuy ➝ Buy$100.00 ➝ $95.00Low
8/4/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00Low
7/24/2023Bank of AmericaLower Target$36.00 ➝ $23.00Low
7/21/2023Morgan StanleyLower TargetEqual Weight$27.00 ➝ $15.00Low
7/21/2023The Goldman Sachs GroupLower TargetBuy$51.00 ➝ $28.00Low
7/21/2023BarclaysLower TargetOverweight$59.00 ➝ $41.00Low
7/20/2023Needham & Company LLCLower TargetBuy$32.00 ➝ $22.00Low
7/20/2023HC WainwrightReiterated RatingBuy ➝ Buy$100.00Low
5/5/2023SVB SecuritiesLower Target$43.00 ➝ $42.00Low
4/19/2023Needham & Company LLCReiterated RatingBuy$32.00Low
4/4/2023Morgan StanleyBoost TargetEqual Weight$25.00 ➝ $27.00Low
3/6/2023HC WainwrightLower TargetBuy$125.00 ➝ $100.00Low
3/6/2023JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$35.00 ➝ $34.00Low
2/24/2023Needham & Company LLCReiterated RatingBuy$32.00N/A
2/21/2023The Goldman Sachs GroupUpgradeNeutral ➝ Buy$41.00 ➝ $53.00Low
1/27/2023SVB LeerinkLower TargetOutperform$45.00 ➝ $43.00Low
1/27/2023Morgan StanleyUpgradeUnderweight ➝ Equal Weight$18.00 ➝ $30.00Low
11/4/2022Morgan StanleyBoost TargetUnderweight$15.00 ➝ $18.00Low
11/4/2022SVB LeerinkBoost TargetOutperform$40.00 ➝ $45.00Low
11/4/2022Needham & Company LLCLower TargetBuy$35.00 ➝ $32.00Low
9/14/2022SVB LeerinkInitiated CoverageOutperform$40.00Low
9/9/2022Morgan StanleyInitiated CoverageUnderweight$15.00Low
8/15/2022BarclaysLower Target$67.00Low
7/14/2022HC WainwrightReiterated RatingBuy$125.00Low
5/12/2022HC WainwrightLower Target$250.00 ➝ $125.00High
5/2/2022HC WainwrightReiterated RatingBuy$200.00High
3/30/2022HC WainwrightLower TargetBuy$300.00 ➝ $200.00High
3/28/2022Needham & Company LLCLower TargetBuy$80.00 ➝ $45.00High
3/3/2022Robert W. BairdUpgradeUnderperform ➝ Neutral$36.00 ➝ $28.00Low
12/21/2021HC WainwrightBoost TargetBuy$200.00 ➝ $300.00High
12/21/2021Robert W. BairdDowngradeNeutral ➝ Underperform$36.00High
12/8/2021HC WainwrightReiterated RatingBuy$199.00Low
11/30/2021HC WainwrightBoost TargetBuy$135.00 ➝ $200.00High
11/17/2021Needham & Company LLCReiterated RatingBuy$79.00High
10/25/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$29.00 ➝ $37.00Medium
9/22/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$64.00 ➝ $62.00High
8/6/2021BarclaysLower TargetOverweight$96.00 ➝ $71.00Medium
6/28/2021Needham & Company LLCReiterated RatingBuy$80.00Low
4/16/2021Needham & Company LLCReiterated RatingBuy$80.00High
3/8/2021HC WainwrightBoost TargetBuy$125.00 ➝ $135.00Low
3/8/2021Needham & Company LLCBoost TargetBuy$75.00 ➝ $80.00N/A
3/3/2021The Goldman Sachs GroupBoost TargetBuy$59.00 ➝ $61.00High
3/2/2021Needham & Company LLCBoost TargetBuy$62.00 ➝ $75.00High
2/25/2021BarclaysBoost TargetPositive ➝ Overweight$61.00 ➝ $77.00High
1/27/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$30.00High
1/20/2021HC WainwrightBoost TargetBuy$100.00 ➝ $125.00Medium
12/25/2020Robert W. BairdReiterated RatingSell$24.00N/A
12/24/2020Robert W. BairdReiterated RatingSell$24.00N/A
10/7/2020HC WainwrightBoost TargetBuy$80.00 ➝ $100.00Low
10/5/2020Bank of AmericaInitiated CoverageBuy$55.00 ➝ $55.00High
9/21/2020HC WainwrightBoost TargetBuy$75.00 ➝ $80.00High
9/14/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$48.00 ➝ $54.00Low
9/11/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$30.00 ➝ $29.00Low
8/31/2020The Goldman Sachs GroupBoost TargetNeutral$43.00 ➝ $48.00High
8/24/2020HC WainwrightReiterated RatingBuy$75.00High
8/20/2020Needham & Company LLCInitiated CoverageBuy$62.00Medium
8/12/2020BarclaysBoost TargetOverweight$44.00 ➝ $61.00Low
5/13/2020BarclaysBoost TargetOverweight$41.00 ➝ $44.00High
3/29/2020BarclaysReiterated RatingBuy$41.00High
3/27/2020Robert W. BairdBoost TargetUnderperform$17.00 ➝ $20.00Medium
3/19/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$26.00High
3/13/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$37.00High
2/27/2020Robert W. BairdDowngradeNeutral ➝ Underperform$17.00High
2/4/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$25.00 ➝ $26.00Low
11/19/2019CowenInitiated CoverageBuyMedium
11/13/2019Robert W. BairdInitiated CoverageNeutralLow
11/5/2019The Goldman Sachs GroupInitiated CoverageBuy$37.00Medium
11/5/2019BarclaysInitiated CoverageOverweight$25.00Medium
11/5/2019JPMorgan Chase & Co.Initiated CoverageOverweight$25.00Medium
11/5/2019CowenInitiated CoverageOutperformMedium
(Data available from 5/25/2019 forward)

News Sentiment Rating

0.56 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/28/2023
  • 4 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/27/2023
  • 2 very positive mentions
  • 8 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
12/27/2023
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 13 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
2/25/2024
  • 5 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/26/2024
  • 9 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 11 very positive mentions
  • 21 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/25/2024

Current Sentiment

  • 11 very positive mentions
  • 21 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Vir Biotechnology logo
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $10.55
Low: $10.51
High: $10.83

50 Day Range

MA: $9.46
Low: $7.63
High: $11.37

52 Week Range

Now: $10.55
Low: $7.61
High: $27.48

Volume

479,615 shs

Average Volume

957,612 shs

Market Capitalization

$1.44 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.47

Frequently Asked Questions

What sell-side analysts currently cover shares of Vir Biotechnology?

The following Wall Street research analysts have issued stock ratings on Vir Biotechnology in the last year: Bank of America Co., Barclays PLC, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for VIR.

What is the current price target for Vir Biotechnology?

7 Wall Street analysts have set twelve-month price targets for Vir Biotechnology in the last year. Their average twelve-month price target is $33.57, suggesting a possible upside of 218.2%. HC Wainwright has the highest price target set, predicting VIR will reach $110.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $12.00 for Vir Biotechnology in the next year.
View the latest price targets for VIR.

What is the current consensus analyst rating for Vir Biotechnology?

Vir Biotechnology currently has 3 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for VIR.

What other companies compete with Vir Biotechnology?

How do I contact Vir Biotechnology's investor relations team?

Vir Biotechnology's physical mailing address is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. The company's listed phone number is 415-906-4324 and its investor relations email address is [email protected]. The official website for Vir Biotechnology is www.vir.bio. Learn More about contacing Vir Biotechnology investor relations.